Bastit V, et al. - In unselected recurrent and/or metastatic head and neck cancer patients (R/MHNC), researchers assessed the benefit of cetuximab (Cx) addition to platinum-based and 5-fluorouracil chemotherapy (PFU) according to KRAS-LCS6 variant status. Findings suggested the probable association of PFU + Cx combination in unselected population of R/MHNC regardless the KRAS-LCS6 variant status. Multivariate analysis suggested that addition of Cx to PFU was the only factor significantly related to a better PFS.